Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899195 · ClinicalTrials.gov registry record · Phase 2
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
A Phase 2 study, sponsored by PrECOG.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT02899195 is a Phase 2 study that has completed, run by PrECOG. The registered enrollment target is 55 participants.
The verdict
NCT02899195, a Phase 2 study, has completed, sponsored by PrECOG.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
Patients with pleural mesothelioma that can not be surgically removed will receive durvalumab, in combination with standard chemotherapy of pemetrexed and cisplatin as first-line treatment. Durvalumab is a type of drug called a monoclonal antibody (a type of protein). Laboratory tests show that it works by allowing the immune system to detect your cancer and reactivates the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS).
Interventions
- DRUG Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-06-13 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02899195
The ClinicalTrials.gov registry entry for NCT02899195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Durvalumab is the first listed.
NCT02899195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02899195 about?
NCT02899195 is a clinical study titled "Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma". Patients with pleural mesothelioma that can not be surgically removed will receive durvalumab, in combination with standard chemotherapy of pemetrexed and cisplatin as first-line treatment. Durvalumab is a type of drug called a monoclonal antibody (a type of protein). Laboratory tests show that it ...
What is the current status of trial NCT02899195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2017-06-13. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT02899195?
The interventions under investigation include: Durvalumab (DRUG).
Who is sponsoring clinical trial NCT02899195?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.